Finasteride vs RU-58841
FDA Approved vs Limited Research
compatible Different mechanisms of action. RU-58841 is a topical androgen receptor antagonist, while finasteride reduces DHT production systemically. Some users combine them for a multi-target approach to hair loss, though RU-58841 lacks FDA approval.
Molecular Data
Finasteride RU-58841
Weight 372.54 Da 369.34 Da
Half-life 6-8 hours (DHT suppression persists ~24 hours) ~1 hour topically (very short systemic half-life)
Type Synthetic 4-azasteroid compound Non-steroidal anti-androgen
Key Benefits
Finasteride
01 Reduces scalp DHT by approximately 66% at 1mg daily
02 Slows or stops hair loss progression in roughly 90% of men
03 Produces visible hair regrowth in approximately 48% of men within 1-2 years
04 FDA-approved with over 25 years of clinical use and long-term safety data
05 Convenient once-daily oral dosing with no injections required
06 Well-characterized side effect profile with low incidence of adverse events
07 Can be combined with minoxidil for enhanced efficacy
RU-58841
01 Blocks DHT directly at the androgen receptor in hair follicles without reducing systemic DHT levels
02 Extremely short systemic half-life limits risk of systemic anti-androgenic side effects
03 Different mechanism of action from finasteride/dutasteride, allowing combination therapy
04 Animal studies demonstrated significant hair regrowth in androgen-dependent alopecia models
05 Topical application targets the site of action directly
06 Does not interfere with systemic testosterone or DHT levels
Side Effects
Finasteride
Decreased libido (reported in 1.8% of men in clinical trials vs 1.3% placebo)
Erectile dysfunction (reported in 1.3% vs 0.7% placebo)
Decreased ejaculate volume (reported in 0.8% vs 0.4% placebo)
RU-58841
Scalp irritation, dryness, or itching at the application site (often related to the vehicle/solvent rather than RU-58841 itself)
Contact dermatitis in sensitive individuals
Scalp flaking or peeling
Contraindications
Women who are pregnant or may become pregnant (finasteride is teratogenic and can cause abnormalities of external genitalia in a male fetus; even handling crushed tablets poses a risk)
Women who are breastfeeding
Known hypersensitivity to finasteride or any component of the formulation
Severe hepatic impairment (finasteride is metabolized by the liver)
Pediatric patients (not indicated for use in children)
Women who are pregnant or may become pregnant (anti-androgens can cause feminization of a male fetus)
Women who are breastfeeding
Known hypersensitivity to RU-58841 or related non-steroidal anti-androgens
Active scalp infections, open wounds, or severely compromised skin barrier on the scalp
Individuals taking systemic anti-androgens (risk of additive anti-androgenic effects)
Research Evidence
Finasteride RU-58841
Status FDA Approved Limited Research
References 5 studies 4 studies
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.